Total Payments
$343.82
2024 Payments
$165.63
Companies
5
Transactions
15
Medicare Patients
1,800
Medicare Billing
$91,866
Payment Breakdown by Category
Food & Beverage$343.82 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $343.82 | 15 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $190.01 | 10 | $0 (2024) |
| Daiichi Sankyo Inc. | $96.99 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $29.55 | 2 | $0 (2017) |
| Chiesi USA, Inc. | $13.65 | 1 | $0 (2017) |
| Incyte Corporation | $13.62 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $165.63 | 8 | ABBVIE INC. ($165.63) |
| 2022 | $24.38 | 2 | ABBVIE INC. ($24.38) |
| 2018 | $13.62 | 1 | Incyte Corporation ($13.62) |
| 2017 | $140.19 | 4 | Daiichi Sankyo Inc. ($96.99) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: NEUROSCIENCE | ||||||
| 08/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.20 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.03 | General |
| Category: NEUROSCIENCE | ||||||
| 03/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.51 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.69 | General |
| Category: NEUROSCIENCE | ||||||
| 03/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $108.03 | General |
| Category: NEUROSCIENCE | ||||||
| 02/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.65 | General |
| Category: NEUROSCIENCE | ||||||
| 01/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.11 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.52 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.09 | General |
| Category: Oncology | ||||||
| 07/12/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: Oncology | ||||||
| 03/30/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $96.99 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/19/2017 | Chiesi USA, Inc. | CUROSURF (Drug) | Food and Beverage | Cash or cash equivalent | $13.65 | General |
| Category: NEONATAL | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 8 | 456 | 754 | $104,698 | $22,336 |
| 2020 | 14 | 1,344 | 2,206 | $291,160 | $69,529 |
Total Patients
1,800
Total Services
2,960
Medicare Billing
$91,866
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2021 | 207 | 352 | $51,396 | $9,907 | 19.3% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2021 | 50 | 86 | $18,860 | $5,510 | 29.2% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2021 | 40 | 95 | $12,488 | $2,096 | 16.8% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2021 | 20 | 53 | $5,799 | $1,727 | 29.8% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2021 | 46 | 55 | $8,196 | $1,496 | 18.3% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2021 | 40 | 50 | $3,260 | $1,036 | 31.8% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2021 | 38 | 42 | $4,026 | $361.69 | 9.0% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2021 | 15 | 21 | $673.00 | $202.18 | 30.0% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2020 | 569 | 974 | $136,962 | $28,626 | 20.9% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2020 | 150 | 245 | $48,540 | $16,197 | 33.4% |
| 88341 | Special stained specimen slides to examine tissue | Facility | 2020 | 72 | 260 | $32,842 | $5,890 | 17.9% |
| 88360 | Microscopic genetic analysis of tumor | Facility | 2020 | 60 | 117 | $11,583 | $3,951 | 34.1% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2020 | 25 | 33 | $8,707 | $3,848 | 44.2% |
| 88342 | Tissue or cell analysis by immunologic technique | Facility | 2020 | 100 | 105 | $13,896 | $2,903 | 20.9% |
| 88331 | Pathology examination of tissue during surgery | Facility | 2020 | 33 | 54 | $10,600 | $2,692 | 25.4% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2020 | 69 | 86 | $4,680 | $1,836 | 39.2% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2020 | 125 | 144 | $13,680 | $1,293 | 9.4% |
| 88344 | Special stained specimen slides to examine tissue | Facility | 2020 | 26 | 30 | $3,750 | $923.26 | 24.6% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2020 | 62 | 81 | $2,025 | $805.40 | 39.8% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2020 | 23 | 44 | $2,200 | $425.91 | 19.4% |
| 88300 | Pathology examination of tissue using a microscope, limited examination | Facility | 2020 | 18 | 21 | $735.00 | $74.71 | 10.2% |
| 88302 | Pathology examination of tissue using a microscope | Facility | 2020 | 12 | 12 | $960.00 | $65.49 | 6.8% |
About Dr. Robert Byrd, M.D
Dr. Robert Byrd, M.D is a Pediatric Pathology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821106550.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Byrd, M.D has received a total of $343.82 in payments from pharmaceutical and medical device companies, with $165.63 received in 2024. These payments were reported across 15 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($343.82).
As a Medicare-enrolled provider, Byrd has provided services to 1,800 Medicare beneficiaries, totaling 2,960 services with total Medicare billing of $91,866. Data is available for 2 years (2020–2021), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Pathology
- Other Specialties Pediatric Pathology
- Location Chicago, IL
- Active Since 08/25/2006
- Last Updated 01/12/2026
- Taxonomy Code 207ZP0213X
- Entity Type Individual
- NPI Number 1821106550
Products in Payments
- VRAYLAR (Drug) $165.63
- Movantik (Drug) $96.99
- OPDIVO (Biological) $29.55
- CUROSURF (Drug) $13.65
- JAKAFI (Drug) $13.62
- UBRELVY (Drug) $12.52
- QULIPTA (Drug) $11.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.